Lilly’s Type II JAK2 Inhibitor Shows Early Promise in Myelofibrosis
As reported on MedCity News, Eli Lilly has reported encouraging early-stage clinical data for AJ1-11095, an investigational therapy for myelofibrosis acquired through its recent purchase of Ajax Therapeutics. Findings, presented…